PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

Rhea-AI Summary

PolyPid (Nasdaq: PYPD) will release its second quarter 2026 financial results and operational highlights before U.S. market open on Wednesday, August 12, 2026. Management will host a conference call and webcast at 8:30 AM Eastern Time to review results and discuss business operations.

Registration for the call is recommended at least five minutes before start, with a separate webcast link available for listen-only participants. PolyPid is a biopharmaceutical company focused on long-acting, controlled-release drugs; its lead product D-PLEX₁₀₀ met primary and key secondary endpoints in the Phase 3 SHIELD II surgical site infection prevention trial.

Market reaction after 2Q26 earnings report: PYPD +5.39%

+5.39% $4.30

15m delay

+5.39% Vs previous close

$4.30 Last Price

$4.04 $4.30 Day Range

$75.78M Market Cap

0.1x Rel. Volume

Following this news, PYPD has gained 5.39%, reflecting a notable positive market reaction. Our momentum scanner has triggered 3 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $4.30.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

PYPD's two prior earnings-date notices were followed by -0.44% and -1.67% 24-hour reactions. That hi...

Analysis

PYPD's two prior earnings-date notices were followed by -0.44% and -1.67% 24-hour reactions. That history frames this release as scheduling information, while the August 12 report and low short positioning are the relevant items to watch.

Key Figures

Reporting Period: Q2 2026 Report Date: August 12, 2026 Conference Call Time: 8:30 AM Eastern Time +2 more

5 metrics

Reporting Period Q2 2026 Financial results announcement

Report Date August 12, 2026 Before the open of U.S. financial markets

Conference Call Time 8:30 AM Eastern Time Results discussion and business update

Registration Lead Time 5 minutes Suggested minimum registration time before the call

Trial Phase Phase 3 SHIELD II trial

Previous Earnings date Reports

2 past events · Latest: May 06 (Neutral)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
May 06	earnings date	Neutral	-0.4%	Scheduled Q1 2026 results and webcast; 24-hour reaction was -0.44%.
Jan 28	earnings date	Neutral	-1.7%	Scheduled Q4 2025 results and cited anticipated NDA submission; reaction was -1.67%.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Both prior earnings-date notices were followed by negative 24-hour price reactions.

Key Terms

controlled-release, phase 3, primary endpoint, secondary endpoints

4 terms

controlled-release technical

"develops long-acting, controlled-release drugs designed to deliver therapy"

A controlled-release medicine is a drug formulation designed to release its active ingredient gradually over a set period instead of all at once. Like a slow-drip faucet that keeps a steady flow rather than a single pour, it helps maintain more stable drug levels in the body, which can affect dosing schedules, patient adherence, manufacturing complexity, regulatory review, patent life, and potential market value for companies that make or sell the product.

phase 3 medical

"successfully met its primary and all key secondary endpoints in the landmark Phase 3"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

primary endpoint medical

"successfully met its primary and all key secondary endpoints"

The primary endpoint is the single main result a clinical study is designed to measure to decide if a treatment works, like the finish line in a race that tells you who won. Investors care because meeting or missing this goal drives regulatory decisions, future sales expectations and stock value — it turns trial data into a clear yes-or-no signal about a drug’s commercial prospects.

secondary endpoints medical

"met its primary and all key secondary endpoints in the landmark Phase 3"

Secondary endpoints are the additional outcomes measured in a clinical study beyond the main goal; they can include effects on symptoms, quality of life, safety measures, or other health indicators. For investors, they matter because positive or negative secondary results can strengthen or weaken the overall story about a treatment’s benefits and risks—like seeing not only that a car reaches its destination (primary goal) but also how comfortable and efficient the ride was (secondary findings).

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PETACH TIKVA, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will report its second quarter 2026 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 12, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.

Conference Call Dial-In & Webcast Information:

Date:	Wednesday, August 12, 2026
Time:	8:30 AM Eastern Time
Conference Call:	https://register-conf.media-server.com/register/BI9a8ec61eabe249f6a1e931836c819ce8
Webcast:	https://edge.media-server.com/mmc/p/3mbsv986

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid's lead product, D-PLEX₁₀₀, successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site infections. Guided by a commitment to precision and innovation, PolyPid is redefining how therapies perform and raise the standard of patient care. For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.

Company Contact:
PolyPid Ltd.
Ori Warshavsky
908-858-5995
IR@Polypid.com

Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
polypid@arxhq.com

FAQ

When will PolyPid (PYPD) report its Q2 2026 financial results?

PolyPid will report its Q2 2026 financial results on Wednesday, August 12, 2026, before the U.S. market opens. According to PolyPid, the release will be followed by a conference call and webcast at 8:30 AM Eastern Time to discuss results and operations.

What time is PolyPid (PYPD) Q2 2026 earnings conference call and how can investors join?

PolyPid’s Q2 2026 earnings conference call starts at 8:30 AM Eastern Time on August 12, 2026. According to PolyPid, investors can register for the call via the provided conference link or access a listen-only webcast through a dedicated media-server URL.

How can I access the PolyPid (PYPD) Q2 2026 results webcast on August 12, 2026?

Investors can access PolyPid’s Q2 2026 results webcast at https://edge.media-server.com/mmc/p/3mbsv986. According to PolyPid, those not planning to ask questions are encouraged to use the webcast option instead of the phone conference line for listening.

What does PolyPid say about its lead product D-PLEX100 and the SHIELD II Phase 3 trial?

PolyPid reports that its lead product D-PLEX₁₀₀ met the primary and all key secondary endpoints in the Phase 3 SHIELD II trial. According to PolyPid, this study evaluated D-PLEX₁₀₀ for preventing surgical site infections, supporting its controlled-release, site-directed therapeutic approach.

What is PolyPid’s main therapeutic focus as of the Q2 2026 results announcement?

PolyPid focuses on developing long-acting, controlled-release drugs that deliver therapy directly at the site of care. According to PolyPid, its pipeline targets critical unmet needs across surgical care, metabolic diseases, and other areas, anchored by its lead product D-PLEX₁₀₀ and the SHIELD II trial results.